Wang · The Journal of pharmacology and experimental therapeutics 2003 · in vivo animal clearance and microperfusion study · n=?

The effects of the potassium channel opener minoxidil on renal electrolytes transport in the loop of henle.

Cited 25 times in the scientific literature.

Level 5 - mechanism / opinion, no new human data

Animal physiological study with in vivo microperfusion and clearance measurements.

PubMed 12538840 · doi:10.1124/jpet.102.043380 · record verified 2026-08-29

What was done

Researchers evaluated the effects of the K(ATP) channel opener minoxidil on renal electrolyte transport (Na+, K+, Ca2+, Mg2+) and fluid reabsorption in the loop of Henle using renal clearance and in vivo microperfusion techniques. Systemic effects were measured following intravenous injection of minoxidil (1.5 mg/kg), and direct tubular transport effects were assessed by adding minoxidil to loop of Henle perfusion fluid.

What was found

Intravenous minoxidil (1.5 mg/kg) decreased urine volume by 63%, fractional Na+ excretion (FENa) by 58%, and fractional Mg2+ excretion (FEMg) by 37%, with a 12% drop in blood pressure and a 15% reduction in glomerular filtration rate. Excretion of K+ and Ca2+ did not change significantly. Direct microperfusion of the loop of Henle with minoxidil significantly increased fluid absorption (Jv) by 44% (from 8.32 to 11.95 nl/min), Na+ absorption (JNa) by 14% (from 1.96 to 2.34 nmol/min), Cl- absorption (JCl) by 21% (from 1.72 to 2.08 nmol/min), and K+ absorption (JK) by 57% (from 35.8 to 56.4 pmol/min).

Why it matters

This study delineates the cellular mechanism underlying minoxidil-associated fluid and sodium retention, demonstrating that K(ATP) opening directly enhances Na/2Cl/K-cotransporter activity in the thick ascending limb.

Limits

The abstract does not state the animal species or sample size. The systemic clearance results are confounded by simultaneous drops in blood pressure and glomerular filtration rate, and these animal microperfusion findings cannot be directly assumed to fully match human clinical pharmacology.

Cited by